PP_1170x120_10-25-21

Patrick Desbiens

GSK ships 2018-2019 seasonal influenza vaccines for U.S. market

GSK ships 2018-2019 seasonal influenza vaccines for U.S. market

PHILADELPHIA — GlaxoSmithKline (GSK) today announced it will begin shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2018-19 flu season, immediately following licensing and lot-release approval from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research. The U.S. Centers for Disease Control and Prevention (CDC) estimates that

GSK’s FluLaval gains expanded age indication

GSK’s FluLaval gains expanded age indication

PHILADELPHIA —  GlaxoSmithKline has received approval from the Food and Drug Administration’s Center for Biologics Evaluation and Research expanding the indication for FluLaval Quadrivalent flu vaccine to include use in children ages 6 months and older. GSK said that previously FluLaval Quadrivalent was only cleared for active immunization against influenza A subtype viruses and type